Melanoma and carcinoma are both skin cancers, but they start in different types of cells, behave very differently, and carry very different levels of risk. The core distinction: carcinomas (basal cell and squamous cell) arise from the ordinary skin cells that form your outer layer of skin, while melanoma develops from the pigment-producing cells that give skin its color. That difference in origin explains why melanoma is far more dangerous, even though it’s far less common.
They Start in Different Cells
Your skin’s outermost layer, the epidermis, contains several types of cells. Basal cell carcinoma grows from cells at the bottom of the epidermis, the layer that continuously produces new skin cells. Squamous cell carcinoma develops from the flat cells that make up most of the epidermis’s upper layers. Both are cancers of the skin’s structural cells.
Melanoma is something else entirely. It originates in melanocytes, specialized cells scattered along the base of the epidermis that produce the pigment responsible for skin color. These cells trace back to neural crest tissue during embryonic development, meaning they share a lineage with nerve cells rather than ordinary skin cells. That different biological origin is part of why melanoma behaves more aggressively. It can invade downward through the epidermis, dermis, and even into the fat layer beneath the skin.
How They Look on Your Skin
Because these cancers come from different cell types, they look noticeably different on the surface. Basal cell carcinoma typically appears as a pink or flesh-colored bump with a pearly or waxy quality, sometimes with a sunken center and tiny blood vessels visible on the surface. It tends to bleed easily if scratched or bumped. Squamous cell carcinoma looks more like a raised, dull-red patch or sore, often with a thick, crusted, or scaly surface that may ulcerate.
Melanoma, by contrast, usually involves color. The National Cancer Institute’s ABCDE rule is the standard way to spot it early:
- Asymmetry: one half of the mole doesn’t match the other
- Border: edges are ragged, notched, or blurred
- Color: uneven shading with mixtures of black, brown, tan, and sometimes white, red, pink, or blue
- Diameter: larger than about 6 millimeters (roughly the size of a pencil eraser), though melanomas can be smaller
- Evolving: the spot has changed in size, shape, or color over recent weeks or months
A changing mole is the single most important warning sign. Carcinomas tend to appear as new growths, while melanomas often develop within or near an existing mole.
Growth Speed and Spread
This is where the differences become critical. Basal cell carcinoma is slow-growing and almost never spreads to other parts of the body. It can cause local damage if left untreated for years, growing into nearby tissue, but it stays put. Squamous cell carcinoma also rarely spreads, though it does so more often than basal cell. Both are highly treatable when caught early.
Melanoma is a different threat. It can metastasize, meaning cancer cells break away from the original tumor and travel through the lymph system or bloodstream to distant organs like the lungs, liver, or brain. About 5% of melanoma cases are already metastatic at the time of diagnosis. The staging system for melanoma reflects this danger: it tracks tumor thickness down to fractions of a millimeter, whether the surface is ulcerated, how many lymph nodes are involved, and whether the cancer has reached distant sites. A melanoma less than 0.8 millimeters thick without ulceration is the earliest stage. One thicker than 4 millimeters with ulceration is among the most advanced primary tumors. Every fraction of depth matters for prognosis.
Survival Rates Tell the Story
Basal cell carcinoma has a five-year survival rate close to 100%. Squamous cell carcinoma sits at about 99% when detected early, though advanced cases fare worse. Cancer registries don’t even formally track survival statistics for these two cancers because deaths from them are so uncommon.
Melanoma’s survival depends heavily on when it’s found. Caught before it spreads, it’s highly survivable. But once melanoma metastasizes to distant organs, the five-year survival rate drops to about 35%. That gap between early and late detection is wider for melanoma than for almost any other common cancer, which is why skin checks matter so much.
UV Exposure Affects Them Differently
Ultraviolet radiation from the sun is the biggest environmental risk factor for all three skin cancers, but the pattern of exposure matters. Squamous cell carcinoma is linked to long-term, cumulative sun exposure, the kind that adds up over decades of outdoor work. Basal cell carcinoma correlates more with intense, intermittent exposure, like occasional severe sunburns. Melanoma is tied specifically to recreational sun exposure and a history of sunburns, particularly blistering burns in childhood or adolescence.
Genetics also play a role. For melanoma, variations in the MC1R gene are particularly significant. This gene controls a receptor involved in skin and hair pigmentation, and certain variants reduce your skin’s natural UV protection, making you more sun-sensitive. Other genes involved in DNA repair and the body’s antioxidant defenses, like the gene encoding catalase (a key enzyme that protects cells from oxidative damage), also interact with sun exposure to influence melanoma risk. Basal and squamous cell carcinomas have their own genetic interactions with UV exposure, but melanoma’s genetic component is especially strong. People with fair skin, red or blond hair, and a family history of melanoma face the highest risk.
Treatment Is More Complex for Melanoma
For basal cell and squamous cell carcinomas, treatment is usually straightforward: surgical removal of the lesion. Because these cancers rarely spread, removing the growth and a margin of surrounding tissue is often the only step needed. Several techniques exist depending on the size and location, but the principle is the same: cut it out, confirm clear margins, and you’re typically done.
Melanoma treatment starts with surgery too, but often doesn’t end there. For thicker melanomas or those that have reached nearby lymph nodes, immunotherapy has become a standard part of care. These treatments help the immune system recognize and attack melanoma cells throughout the body. In some cases, immunotherapy is given before surgery to shrink the tumor, then continued afterward. The transformation in melanoma treatment over the past decade has been dramatic, with immune-based therapies significantly improving outcomes for people with advanced disease. However, these treatments can come with notable side effects, and not every patient with early-stage melanoma will need them.
How Diagnosis Differs
When a doctor suspects any skin cancer, a biopsy is the definitive step. But the approach differs based on what’s suspected. For a lesion that might be melanoma, an excisional biopsy (removing the entire lesion with a margin of normal skin) is preferred because pathologists need to measure the tumor’s full thickness accurately. That thickness measurement drives every staging and treatment decision that follows. If the lesion is too large or in a difficult location to remove entirely, a punch biopsy targeting the thickest part is an alternative.
For suspected carcinomas, the biopsy approach is more flexible. Shave biopsies, which remove just the raised portion of a growth, are commonly used because depth measurement isn’t as critical for treatment planning. The overall diagnostic process is simpler and faster, matching the lower-risk nature of these cancers.